Overview

Industry Leading TCR Pipeline Targeting Solid Tumors

Cancer is a leading cause of death worldwide and is characterized by the uncontrolled growth of abnormal cells whose ability to evade the immune system is key. Adaptimmune’s affinity enhanced T-cell therapies work with the immune system to improve detection and targeting of cancer cells, resulting in destruction of those cancer cells. We believe that the unique potential of immunotherapy will revolutionize the treatment of oncology in the future and Adaptimmune is at the forefront of immunotherapy development.

SPEAR® T-cell therapies targeting MAGE-A10, MAGE-A4, AFP and NY-ESO* are progressing through clinical studies in multiple cancer types.

Our Pipeline

Adaptimmune is developing an industry leading TCR pipeline in solid tumors, and has a deep pipeline of identified and proprietary targets for further TCR development.

Program Indications Pre-Clinical Phase I/II Registration
MAGE-A10 Urothelial
Melanoma
Head & Neck
Pre-Clinical Phase complete
Phase I/II Phase in progress
Registration Phase not started
NSCLC (lung)
Pre-Clinical Phase complete
Phase I/II Phase in progress
Registration Phase not started
MAGE-A4 Urothelial
Melanoma
Ovarian
NSCLC (lung)
Esophageal
Gastric
Synovial Sarcoma
MRCLS 1
Head and Neck
Pre-Clinical Phase complete
Phase I/II Phase in progress
Registration Phase not started
AFP Hepatocellular
Pre-Clinical Phase complete
Phase I/II Phase in progress
Registration Phase not started
Additional Spear T-Cell Candidates
Multiple targets/Multiple Indications
Pre-Clinical Phase in progress
Phase I/II Phase not started
Registration Phase not started
  1. MRCLS = myxoid/round cell liposarcoma

NY-ESO

Program Indications Pre-Clinical Phase I/II Registration
NY-ESO 1 Synovial Sarcoma
Pre-Clinical Phase complete
Phase I/II Phase in progress
Registration Phase not started
MRCLS 2
Pre-Clinical Phase complete
Phase I/II Phase in progress
Registration Phase not started
NSCLC (lung)
Pre-Clinical Phase complete
Phase I/II Phase in progress
Registration Phase not started
NY-ESO + Keytruda Multiple Myeloma 3
Pre-Clinical Phase complete
Phase I/II Phase in progress
Registration Phase not started
  1. Adaptimmune’s accrual complete. Option exercised by GSK on 7th September 2017
  2. MRCLS = myxoid/round cell liposarcoma
  3. Ongoing

GSK exercised its option to exclusively license the right to research, develop, and commercialize NY-ESO SPEAR T-cell therapy program in September 2017. Transition of this program to GSK is ongoing.